Blood omega-3 levels were associated with both brain structure and amyloid burden in older adults at elevated Alzheimer's risk. Digest
- Alzheimer's
- Blood-Brain Barrier
- Brain
- Dementia
- Genetics
- Inflammation
- Neurodegeneration
- Neurons
- Omega-3
The genetic variant APOE4 raises Alzheimer's risk and may also make it harder for some omega-3 fats to reach the brain. A new analysis asked whether this genetic difference shapes the relationship between blood omega-3 levels and early brain imaging markers.
The study compared fasting blood omega-3 levels with two kinds of brain scans in 104 cognitively normal older adults. Magnetic resonance imaging (MRI) measured gray matter volume, while positron emission tomography (PET) estimated amyloid-beta deposits, protein buildups that are an early hallmark of Alzheimer's disease. Most participants had elevated amyloid without symptoms, and 44% carried APOE4.
- Higher omega-3 status was linked to larger gray matter volume in an Alzheimer's-relevant brain region.
- Higher omega-3 status also tracked with less amyloid across multiple brain regions.
-
The gray matter link was similar with or without APOE4, while exploratory amyloid analyses found associations across more regions in carriers.
- The amyloid association appeared to be driven primarily by DHA. EPA showed no clear association alone, although the combined DHA/EPA pattern was stronger than the DHA-only pattern.
Brain cells rely on DHA-rich membranes for signaling and structural stability, while chronic amyloid and inflammation can place pressure on those same cells. EPA may reinforce the system through vascular and anti-inflammatory effects. A blood omega-3 profile that supports membranes, circulation, and amyloid clearance could therefore be reflected in measures of both brain structure and amyloid deposition.
You just missed this in your inbox
Every other week our Premium Members received this exact study plus Rhonda's practical commentary and 8+ other hand-picked papers.
Omega-3 status appears to intersect with Alzheimer's-related biology before cognitive symptoms emerge. That relationship may be especially relevant in APOE4 carriers, who may need higher blood levels to overcome impaired omega-3 delivery to the brain.